This case report mentions that TTR-FAP can cause different clinical phenotypes, even due to the same mutation and even in the same family.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is an unusual but life-threatening disease that is autosomal dominant inherited and involves the mutation of the transthyretin (TTR) gene.
📊
Key Findings & Data:A total of 26 patients with TTR-FAP and different mutations, including the p.Glu 109Gln mutation (previously annotated p.
💡
Conclusion & Impact:This case report mentions that TTR-FAP can cause different clinical phenotypes, even due to the same mutation and even in the same family.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is an unusual but life-threatening disease that is autosomal dominant inherited and involves the mutation of the transthyretin (TTR) gene. A total of 26 patients with TTR-FAP and different mutations, including the p.Glu 109Gln mutation (previously annotated p. Glu89Gln), were previously reported in Turkey. Herein, we reported two patients from the same family who had the same p.Glu 109Gln mutation but had different clinical phenotypes. The clinical picture mainly involved polyneuropathy in one patient and cardiac involvement in the other patient. This case report mentions that TTR-FAP can cause different clinical phenotypes, even due to the same mutation and even in the same family.
🔖
Cite This Article
Uyguner, Z. O., Tekin, S., Unluturk, Z., Erdogan, C. (2022). Different phenotypes of transthyretin-associated familial amyloid polyneuropathy due to a mutation in p.Glu109Gln in members of the same family. İstanbul Kuzey Klinikleri, Cilt: 8 - Sayı: 4, 398–401. https://ajindex.com/articles/652007
Uemichi T, Liepnieks JJ, Benson MD. A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. Neurology 1997;48:1667–70
Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med 2012;79:733–48
Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057–62
Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411–23
Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
Durmuş-Tekçe H, Matur Z, Mert Atmaca M, Poda M, Çakar A, Hıdır Ulaş Ü, et al. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey. Neuromuscul Disord 2016;26:441–6
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286–300
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101–10
Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009;103:544–9
Bekircan-Kurt CE, Güneş N, Yılmaz A, Erdem-Özdamar S, Tan E. Three Turkish families with different transthyretin mutations. Neuromuscul Disord 2015;25:686–92
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
Coutinho P, da Silva AL, Lopes J, Resende PE, Da Silva AM, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88–98
Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov 2012;11:185–6.